COVID19 Update: For your safety, you will be asked to use a mask, if you do not have one, a mask will be provided. If a person presents with a temperature, you will be asked to return home and further instructions will be given by your health care team. For our patients protection, no visitors under 18 will be allowed in the offices, there is a limit one (1) visitor per patient if necessary. No visitors are allowed in the chemo infusion room. Telemedicine are available for routine office visits. More Information-PLEASE CLICK HERE

Clinical Trial: 19160

Trial Status: Open
Trial Type: Ovarian
Disease Type: Gynecologic
Trial ID 19160
Sponsor ID 19160

A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK7339-001/ENGOT-ov43/GOG-3036)

Principal Investigator
Robert L. Marsh, MD
5 Locations

Locations

Alexandria Office

Arlington Office

Gainesville Office

Loudoun Office

Fairfax Office

Learn More About This Trial
Other Relevant Trials
Trial ID PLX124-03
Sponsor ID Plexxikon Inc.

A Multicenter, Open-Label, Parallel, Phase 2a Study of PLX2853 Monotherapy in Advanced Gynecological Malignancies with a Known ARID1A Mutation and Phase 1b/2a Study of PLX2853/Carboplatin Combination Therapy in Platinum-Resistant Epithelial Ovarian Cancer

Principal Investigator
Alexander I Spira, MD, PhD, FACP
1 Location
Trial ID 16 233
Sponsor ID

A PHASE III, MULTICENTER, RANDOMIZED, STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, AND BEVACIZUMAB TO PATIENTS WITH NEWLY-DIAGNOSED STAGE III OR STAGE IV OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER

Principal Investigator
Neelima Denduluri, MD, FASCO
6 Locations